D A Ahlquist

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Molecular detection of colorectal neoplasia
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 138:2127-39. 2010
  2. ncbi The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 10:272-7.e1. 2012
  3. ncbi Next-generation stool DNA test accurately detects colorectal cancer and large adenomas
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 142:248-56; quiz e25-6. 2012
  4. ncbi Stool DNA and occult blood testing for screen detection of colorectal neoplasia
    David A Ahlquist
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 149:441-50, W81. 2008
  5. ncbi Stool screening for colorectal cancer: evolution from occult blood to molecular markers
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Chim Acta 315:157-68. 2002
  6. ncbi Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel
    D A Ahlquist
    Division of Gastroenterology and Hepatology, Department of Biostatistics, and Division of Molecular Genetics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 119:1219-27. 2000
  7. ncbi Optimization of CT colonography technique: prospective trial in 180 patients
    J G Fletcher
    Department of Diagnostic Radiology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Radiology 216:704-11. 2000
  8. ncbi Association of Peutz-Jeghers-like mucocutaneous pigmentation with breast and gynecologic carcinomas in women
    L A Boardman
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Medicine (Baltimore) 79:293-8. 2000
  9. ncbi Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative
    R S Wooten
    Department of Medicine, Mayo Clinic, Rochester, MN 55905
    Lasers Surg Med 8:294-300. 1988
  10. ncbi CT colonography without cathartic preparation: feasibility study
    M R Callstrom
    Department of Diagnostic Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiology 219:693-8. 2001

Research Grants

  1. Colorectal Cancer Screening: Fecal Blood vs DNA
    David Ahlquist; Fiscal Year: 2004

Collaborators

Detail Information

Publications34

  1. ncbi Molecular detection of colorectal neoplasia
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 138:2127-39. 2010
    ..This review addresses the biological rationale, technical advances, recent clinical performance data, and remaining issues with molecular screening for colorectal cancer...
  2. ncbi The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 10:272-7.e1. 2012
    ..We compared the sensitivities of a multimarker test for stool DNA (sDNA) and a plasma test for methylated septin 9 (SEPT9) in identifying patients with large adenomas or CRC...
  3. ncbi Next-generation stool DNA test accurately detects colorectal cancer and large adenomas
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 142:248-56; quiz e25-6. 2012
    ..We assessed colorectal neoplasm detection by a next-generation sDNA test and effects of covariates on test performance...
  4. ncbi Stool DNA and occult blood testing for screen detection of colorectal neoplasia
    David A Ahlquist
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 149:441-50, W81. 2008
    ..Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting...
  5. ncbi Stool screening for colorectal cancer: evolution from occult blood to molecular markers
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Chim Acta 315:157-68. 2002
    ..Participation rates for colorectal cancer screening remain low due, in part, to perceived discomfort, potential harm, and high costs with available tools...
  6. ncbi Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel
    D A Ahlquist
    Division of Gastroenterology and Hepatology, Department of Biostatistics, and Division of Molecular Genetics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 119:1219-27. 2000
    ..We explored the feasibility of a stool assay panel of selected DNA alterations in discriminating subjects with colorectal neoplasia from those without...
  7. ncbi Optimization of CT colonography technique: prospective trial in 180 patients
    J G Fletcher
    Department of Diagnostic Radiology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Radiology 216:704-11. 2000
    ..To assess the added benefits of prone positioning in addition to supine positioning and oral iodinated contrast medium for help in the detection of colonic polyps at computed tomographic (CT) colonography...
  8. ncbi Association of Peutz-Jeghers-like mucocutaneous pigmentation with breast and gynecologic carcinomas in women
    L A Boardman
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Medicine (Baltimore) 79:293-8. 2000
    ..In particular, the relative risk for cancer in females with IMMP was significantly increased, as is true in females with PJS. However, LKB1 mutations did not contribute to the development of IMMP in the patients tested...
  9. ncbi Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative
    R S Wooten
    Department of Medicine, Mayo Clinic, Rochester, MN 55905
    Lasers Surg Med 8:294-300. 1988
    ..Other HpD-related complications included skin hyperpigmentation, ocular discomfort, pruritus, pain at injection site, and urticaria. CP and the restrictive measures to avoid it represent major disadvantages of the clinical use of HpD...
  10. ncbi CT colonography without cathartic preparation: feasibility study
    M R Callstrom
    Department of Diagnostic Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiology 219:693-8. 2001
    ..Sensitivity for polyp detection in patients with adequate stool labeling approaches the sensitivity for polyp detection in prepared colons...
  11. ncbi A search for germline APC mutations in early onset colorectal cancer or familial colorectal cancer with normal DNA mismatch repair
    L A Boardman
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Genes Chromosomes Cancer 30:181-6. 2001
    ..All appeared to be polymorphisms present in similar proportions in an average-risk population. We conclude that germline APC mutations do not account for familial MSS (stable microsatellite) CRC associated with few synchronous polyps...
  12. ncbi Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis
    P S Kamath
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 118:905-11. 2000
    ..The response of gastric mucosal lesions in cirrhotic patients with portal hypertension, namely, portal hypertensive gastropathy (PHG) and gastric vascular ectasia (GVE), to transjugular intrahepatic portosystemic shunts (TIPS) is not known...
  13. ncbi Localization of hematoporphyrin. Derivative to human colorectal cancer
    R S Wooten
    Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota 55905
    Cancer 64:1569-76. 1989
    ..6 microgram/g versus 0.1 microgram/g, P less than 0.001). The authors conclude that HpD preferentially localizes to human colorectal cancer and this is relevant to the photodetection and phototherapy of colorectal neoplasia...
  14. ncbi Colorectal cancer prevention and detection. Introduction
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterol Clin North Am 31:xi-xii. 2002
  15. ncbi A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening
    Hongzhi Zou
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 15:1115-9. 2006
    ..This study shows that not all CRCs are associated with increased fecal levels of long DNA. Long DNA degrades with fecal storage, and measures to stabilize this analyte must be considered for optimal use of this marker...
  16. ncbi A novel method to capture methylated human DNA from stool: implications for colorectal cancer screening
    Hongzhi Zou
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Clin Chem 53:1646-51. 2007
    ..Assay of methylated DNA markers in stool is a promising approach for colorectal cancer (CRC) screening. A method to capture hypermethylated CpG islands from stool would enrich target analyte and allow optimal assay sensitivity...
  17. ncbi Highly methylated genes in colorectal neoplasia: implications for screening
    Hongzhi Zou
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 16:2686-96. 2007
    ..Comethylation of these genes is common, and pursuit of complementary markers for methylation-negative neoplasms is a rational strategy to optimize screening sensitivity...
  18. ncbi Stool screening for colorectal cancer: molecular approaches
    Neal K Osborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 128:192-206. 2005
    ..Further marker discovery and technologic refinements should translate into improved test performance and fuel a continued evolution with this screening approach...
  19. ncbi Comparison of the relative sensitivity of CT colonography and double-contrast barium enema for screen detection of colorectal polyps
    C Daniel Johnson
    Department of Radiology, Mayo Clinic Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 2:314-21. 2004
    ..01]). CONCLUSIONS: Double-read CT colonography is significantly more sensitive in detecting polyps than single-read double contrast barium enema. DCBE was significantly more specific than CT colonography...
  20. ncbi Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia
    Paul J Limburg
    Division of Gastroenterology and Hepatology and Department of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 98:2299-305. 2003
    ..Further investigation of tumor-derived, rather than blood-based, biomarkers may be a more rewarding approach to stool screening for colorectal neoplasia...
  21. ncbi Stool-based DNA tests for colorectal cancer: clinical potential and early results
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Rev Gastroenterol Disord 2:S20-6. 2002
    ..Large, multicenter, comparative studies addressing the performance of stool-based DNA testing in the general population will soon be completed and will promise to validate the readiness of this approach for widespread application...
  22. ncbi DNA integrity as a potential marker for stool-based detection of colorectal cancer
    Kevin A Boynton
    Applied Research Group, EXACT Sciences Corporation, 63 Great Road, Maynard, MA 01754, USA
    Clin Chem 49:1058-65. 2003
    ..An assay of fecal DNA integrity may be a useful biomarker for the detection of CRC...
  23. ncbi Colorectal cancer screening with CT colonography, colonoscopy, and double-contrast barium enema examination: prospective assessment of patient perceptions and preferences
    Thomas M Gluecker
    Department of Radiology, Mayo Clinic Rochester, 200 First Street SW, MN 55905, USA
    Radiology 227:378-84. 2003
    ..0% vs 0.4%; P <.001). CONCLUSION: Patients undergoing colorectal cancer screening prefer CT colonography to both colonoscopy and DCBE. The majority of patients experience discomfort and inconvenience with cathartic bowel preparation...
  24. ncbi Contrast-enhanced CT colonography in recurrent colorectal carcinoma: feasibility of simultaneous evaluation for metastatic disease, local recurrence, and metachronous neoplasia in colorectal carcinoma
    J G Fletcher
    Department of Radiology, Mayo Clinic, East-2B, 200 First St, S.W, Rochester, MN 55905, USA
    AJR Am J Roentgenol 178:283-90. 2002
    ..The technique can also serve as a useful adjunct to colonoscopy by detecting local recurrences or metachronous disease that are endoscopically obscure or by serving as a full structural colonic examination when endoscopy is incomplete...
  25. ncbi Second primary colorectal cancer: the consequence of management failure at several potential levels
    Paul J Limburg
    Ann Intern Med 136:335-7. 2002
  26. ncbi Detection of occult upper gastrointestinal tract bleeding: performance differences in fecal occult blood tests
    Gavin C Harewood
    Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:23-8. 2002
    ..003). CONCLUSION: The HQT test detects occult upper GI tract blood loss significantly more frequently than the HO or HS test...
  27. ncbi Detection of colorectal disease by stool defensin assay: an exploratory study
    Hongzhi Zou
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 5:865-8. 2007
    ..We evaluated the neoplasm specificity of HPN1-3 and their discriminant value as stool markers for CRC...
  28. ncbi Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study
    Paul J Limburg
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 101:1872-9. 2006
    ....
  29. ncbi Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia
    Neal K Osborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 4:212-8. 2006
    ..005). CONCLUSIONS: The EYA4 gene promoter is hypermethylated commonly in sporadic and colitic neoplasia and may be associated with gene silencing. EYA4 methylation represents a candidate marker for CUC surveillance...
  30. ncbi Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus
    Hongzhi Zou
    Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Cancer 116:584-91. 2005
    ..Aberrant promoter methylation appears to functionally silence SFRP gene expression in esophageal adenocarcinoma...
  31. ncbi Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma
    Hongzhi Zou
    Department of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 14:830-4. 2005
    ....
  32. ncbi Changing trends in the incidence, stage, survival, and screen-detection of colorectal cancer: a population-based study
    Amit K Gupta
    Division of General Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Clin Gastroenterol Hepatol 3:150-8. 2005
    ..However, the incidence of right-sided cancer remains unaltered and might be less affected by historically used screening interventions. Most CRCs still present symptomatically, and more effective population screening is needed...
  33. ncbi Extracolonic findings at CT colonography: evaluation of prevalence and cost in a screening population
    Thomas M Gluecker
    Department of Radiology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Gastroenterology 124:911-6. 2003
    ..Although such incidental findings add benefit to the screening intervention, moderate incremental costs are incurred based on additional radiologic procedures generated during short-term follow-up...
  34. ncbi Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps
    C Daniel Johnson
    Department of Radiology, Mayo Clinic Rochester, 200 First Street S.W, Rochester, Minnesota 55905, USA
    Gastroenterology 125:311-9. 2003
    ..Specificity, based on large numbers, is high and exhibits excellent agreement among observers...

Research Grants1

  1. Colorectal Cancer Screening: Fecal Blood vs DNA
    David Ahlquist; Fiscal Year: 2004
    ..If the DNA-based test proves to have greater screening accuracy than fecal blood testing, this could translate into more effective cancer control and more efficient use of our limited health care resources. ..